Preliminary exploration of poor prognostic factor IL-33 and its involvement in perioperative immunotherapy in stage II–III lung squamous cell carcinoma: a retrospective cohort study
High IL-33 expression in cancer tissues is associated with poor prognosis in stage II-III LUSC. IL-33 blockade combined with ICIs may provide new treatment regimens and ideas for perioperative immunotherapy in stage II-III LUSC patients.
Authors
- Jinpu Yu (ORCID: https://orcid.org/0000-0002-5982-2266)
- Wolfgang M. Brueckl (ORCID: https://orcid.org/0000-0002-7039-0791)
- Chuangui Zhang
- Fabien Forest (ORCID: https://orcid.org/0000-0001-7582-3923)
- Cuicui Zhao (ORCID: https://orcid.org/0000-0001-6520-7772)
- Pengpeng Liu (ORCID: https://orcid.org/0000-0002-5148-4653)
- Nobuhiko Seki (ORCID: https://orcid.org/0000-0002-0732-5348)
- Yan Liu (ORCID: https://orcid.org/0000-0002-6515-5383)
- Rui Zhang (ORCID: https://orcid.org/0000-0002-9696-0553)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Paracelsus Medizinische Privatuniversität (DE)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Teikyo University (JP)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2024-09-01
- DOI
- https://doi.org/10.21037/jtd-24-1122
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Taiho Pharmaceutical
- Ono Pharmaceutical
- Chugai Pharmaceutical